Decreased expression and activity of G-protein-coupled receptor kinases inperipheral blood mononuclear cells of patients with rheumatoid arthritis

Citation
Ms. Lombardi et al., Decreased expression and activity of G-protein-coupled receptor kinases inperipheral blood mononuclear cells of patients with rheumatoid arthritis, FASEB J, 13(6), 1999, pp. 715-725
Citations number
49
Categorie Soggetti
Experimental Biology
Journal title
FASEB JOURNAL
ISSN journal
08926638 → ACNP
Volume
13
Issue
6
Year of publication
1999
Pages
715 - 725
Database
ISI
SICI code
0892-6638(199904)13:6<715:DEAAOG>2.0.ZU;2-B
Abstract
beta(2)-Adrenergic and chemokine receptor antagonists delay the onset and r educe the severity of joint injury in rheumatoid arthritis. beta(2)-adrener gic and chemokine receptors belong to the G-protein-coupled receptor family whose responsiveness is turned off by the G-protein-coupled receptor kinas e family (GRK-1 to 6). GRKs phosphorylate receptors in an agonist-dependent manner resulting in receptor/G-protein uncoupling via subsequent binding o f arrestin proteins. We assessed the activity of GRKs in lymphocytes of rhe umatoid arthritis (RA) patients by rhodopsin phosphorylation. We found a si gnificant decrease in GRK activity in RA subjects that is mirrored by a dec rease in GRK-2 protein expression. Moreover, GRK-6 protein expression is re duced in RA patients whereas GRK-5 protein levels were unchanged. In search of an underlying mechanism, we demonstrated that proinflammatory cytokines induce a decrease in GRK-2 protein levels in leukocytes from healthy donor s. Since proinflammatory cytokines are abundantly expressed in RA, it may p rovide an explanation for the decrease in GRK-2 expression and activity in patients. No changes in beta(2)-adrenergic receptor number and K-d were det ected. However, RA patients showed a sig nificantly increased cAMP producti on and inhibition of TNF-alpha production by beta(2)-adrenergic stimulation , suggesting that reduced GRK activity is associated with increased sensiti vity to beta(2)-adrenergic activation.